Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Du, Xiaoling ^a   Yang, Jilong ^a,b   Ylipää, Antti ^b,c   Zhu, Ze ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Epithelial growth factor receptor; Gefitinib; Gene amplification; Malignant peripheral nerve sheath tumor; Microarray based comparative genomic hybridization; Targeted therapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3ALPHA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT1 PROTEIN;

ARTICLE; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; OVERALL SURVIVAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NERVE SHEATH NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84890253771     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-93     Document Type: Article

References (40)

1. Treatment of a malignant peripheral nerve sheath tumor. Lin CT, Huang TW, Nieh S, Lee SC, Onkologie 2009 32 503 505
2. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, et al. Ann Surg 2009 249 1014 1022
3. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M, Trent J, Ratner N, Lev DC, Zhang W, Clin Cancer Res 2011 17 7563 7573
4. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, Prayson RA, Guha A, Bridge JA, Ferner RE, et al. Clin Cancer Res 2011 17 1924 1934
5. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Kresse SH, Skarn M, Ohnstad HO, Namlos HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA, Mol Cancer 2008 7 48
6. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M, Clin Cancer Res 2008 14 1015 1024 (Pubitemid 351302546)
7. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, Tamiya S, Matsuda S, Iwamoto Y, Tsuneyoshi M, Oda Y, Clin Cancer Res 2011 17 3771 3782
8. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH, Cho BC, Clin Cancer Res 2012 18 1760 1768
9. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Williams JPWJ, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N, Cell Stem Cell 2008 3 658 669
10. Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. Wu J, Crimmins JT, Monk KR, Williams JP, Fitzgerald ME, Tedesco S, Ratner N, Am J Pathol 2006 168 1686 1696
11. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O, J Neurooncol 2009 94 383 388
12. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W, Cancer 2011 117 4925 4938
13. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y, et al. Mod Pathol 2006 19 788 796 (Pubitemid 43780448)
14. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Riedemann J, Takiguchi M, Sohail M, Macaulay VM, Biochem Biophys Res Commun 2007 355 707 714 (Pubitemid 46330209)
15. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG, Cancer Res 2008 68 8004 8013
16. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, et al. Ann Oncol 2009 20 842 849
17. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG, Mol Cancer Ther 2009 8 821 833
18. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells. Kohli L, Kaza N, Lavalley NJ, Turner KL, Byer S, Carroll SL, Roth KA, Neuro-oncology 2012 14 266 277
19. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, Mautner VF, Schildhaus HU, von Deimling A, Neuro-oncology 2008 10 946 957
20. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN, Cancer Biol Ther 2008 7 1938 1946
21. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG, Neoplasia 2009 11 448 458 442 p following 458
22. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et al. Carcinogenesis 2009 30 1097 1105
23. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT, Clin Cancer Res 2002 8 2273 2285 (Pubitemid 34753601)
24. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, et al. Clin Cancer Res 2004 10 1212 1218 (Pubitemid 38365209)
25. Malignant peripheral nerve sheath tumors. Gupta G, Mammis A, Maniker A, Neurosurg Clin N Am 2008 19 533 543
26. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Yang J, Du X, Surg Oncol 2013 22 53 e57
27. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R, Baker LH, Oncologist 2008 13 459 466 (Pubitemid 351679927)
28. Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Tabone-Eglinger S, Bahleda R, Cote JF, Terrier P, Vidaud D, Cayre A, Beauchet A, Theou-Anton N, Terrier-Lacombe MJ, Lemoine A, et al. Sarcoma 2008 2008 849156
29. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, et al. Cancer Res 2009 69 161 170
30. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R, J Clin Oncol 2012 30 64 e68
31. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, et al. J Clin Oncol 2009 27 3133 3140
32. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, et al. J Clin Oncol 2009 27 3154 3160
33. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, et al. J Clin Oncol 2009 27 3148 3153
34. How does the Schwann cell lineage form tumors in NF1? Carroll SL, Ratner N, Glia 2008 56 1590 1605
35. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. N Engl J Med 2004 350 2129 2139 (Pubitemid 38637993)
36. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA, J Clin Invest 2008 118 2609 2619 (Pubitemid 351949788)
37. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, et al. Cancer 2006 107 1065 1074 (Pubitemid 44291156)
38. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC, Khoury JD, Cancer 2008 113 1453 1461
39. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H, Lab Invest 2004 84 582 587 (Pubitemid 38858467)
40. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, et al. Int J Cancer 2009 125 2991 2994